Aquestive Announces FDA Acceptance of Anaphylm NDA Resubmission, PDUFA Date Set for March 16, 2027

Aquestive reported FDA acceptance of its Anaphylm NDA resubmission, with a PDUFA goal date set for March 16, 2027. The resubmission addresses prior FDA concerns and, if approved, Anaphylm would be the first oral rescue medication for anaphylaxis. Aquestive also aims for a Health Canada submission in Q4 2026.

Original reporting
Published Oct 15, 2026, 11:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 11:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aquestive Announces FDA Acceptance of Anaphylm NDA Resubmission, PDUFA Date Set for March 16, 2027 — source image
Decision brief

The 30-second read

$AQSTBullishMed
01

Why it matters

The acceptance removes a regulatory hurdle and sets a clear timeline, which is a catalyst for the stock.

02

Market read

Regulatory progress for a niche biotech can drive short‑term price movement and influence sector sentiment.

03

What to watch

Potential competition from injectable anaphylaxis treatments and reimbursement uncertainties.

Relevance 8/10Novelty 8/10Timing: today

Background

Aquestive Therapeutics filed an 8‑K announcing FDA acceptance of its NDA resubmission for Anaphylm, an oral rescue drug for anaphylaxis.

Company-level read

Ticker impact

$AQSTBullishHigh confidence
Context

FDA accepted the Anaphylm NDA resubmission and set a PDUFA target date of March 16, 2027.

Expected impact

potential upside as market prices in the FDA acceptance and future review timeline

Evidence & confidence

First report of FDA acceptance; biotech stocks typically rally on such news.

Market effects

May boost confidence in other allergy‑treatment biotech peers.

U.S. biotech sector could see modest gains.

Limited to biotech investors; no broad market effect.

Counterpoint

If the FDA later requests additional data, the initial optimism could reverse.

Key entities

  • Aquestive Therapeutics, Inc.

    Biopharma developing oral anaphylaxis treatment.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.